Aldeyra Therapeutics Inc (ALDX) - News Archive

Unlocking New Frontiers: Aldeyra Therapeutics Expands RASP Platform to Address Central Nervous System Diseases In a groundbreaking announcement during a recent Research & Development webcast, Aldeyra Therapeutics, Inc....

In an exciting development for the treatment of alcohol-associated hepatitis, Aldeyra Therapeutics, Inc., a biotechnology company based in Lexington, Massachusetts, has announced promising results from a Phase 2 clinica...

Biotech Breakthrough: Aldeyra Therapeutics Strategic Moves in Eye Health and Global Investment Horizons In the dynamic world of biotechnology, every announcement can significantly shift the trajectory of a company eithe...

In a notable advancement within oncological therapeutics, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), has recently achieved Orphan Designation from the European Medicines Agency (EMA) for its investigational drug, ADX-21...

Aldeyra Therapeutics Advances Towards FDA Approval for Reproxalap: A Potential Breakthrough in the Treatment of Dry Eye Disease LEXINGTON, Mass. Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a pioneering biotechnology firm...

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has recently found itself in a tumultuous position as investors express concern over the biotech company s stock fluctuations and potential legal issues. Amidst a mixture of pro...

Dry eye disease (DED) remains a prevalent condition affecting millions globally, contributing to significant discomfort and a diminished quality of life. As advances in ophthalmic therapeutics continue to emerge, Aldeyr...

Pioneering Progress: Aldeyra Therapeutics Quest to Revolutionize Dry Eye Treatment and Metabolic Disease Innovations In a significant stride for ocular medicine, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), renowned for i...

Reproxalap: A New Hope for Dry Eye Disease as Aldeyra Therapeutics Resubmits NDA Amid Financial Challenges In a promising stride for individuals plagued by dry eye disease, Aldeyra Therapeutics, Inc. a pioneering biotec...

: Aldeyra Therapeutics, Inc. has made significant strides in the field of ophthalmology following the achievement of the primary endpoint in a Phase 3 clinical trial for its investigational drug, reproxalap, aimed at tr...

In recent news, shareholder rights law firm Johnson Fistel, LLP has initiated an investigation into potential violations of federal and state laws by certain officers of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), Eagle...

Aldeyra Therapeutics, a biotechnology company specializing in immune-mediated and metabolic disease treatments, has recently announced significant progress in the development of new RASP (reactive aldehyde species) modu...

Aldeyra Therapeutics, a pioneering biotechnology company focused on immune-mediated and metabolic diseases, has successfully completed enrollment in a Phase 3 clinical trial for their topical ocular 0.25% reproxalap. Th...

Aldeyra Therapeutics Advances Reproxalap as a Potential Breakthrough Treatment for Dry Eye Disease with Enrollment of First Patient in Phase 3 Clinical TrialLEXINGTON, Mass. - Aldeyra Therapeutics, a pioneering biotechn...

Aldeyra Therapeutics, a leading biotechnology company, recently presented noteworthy updates on their research and development pipeline at the Aldeyra 2024 Research & Development Day in New York City. The event provided...